Cyclobenzaprine Hydrochloride Tablet, Film Coated
Product Images NDC 69097-845
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Cyclobenzaprine Hydrochloride (NDC 69097-845). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)
This is a table that shows the side effects and percentage of patients experiencing these side effects from two different dosages of Cyclobenzaprine HCI Tablets and a placebo. The common side effects are drowsiness, dry mouth, fatigue, and headache. The percentage of patients experiencing these side effects varies based on the dosage. The highest percentage of side effects was observed with the 10mg dose of Cyclobenzaprine.*
Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)
Cyclobenzaprine 10 mg
This is a medication called Cyclobenzaprine Hydrochloride, used for the relief of muscle pain and stiffness. The usual adult dosage is not provided. The medication comes in tablet form and should be dispensed in a well-dosed container. It is manufactured for Cipla USA, Inc. and comes in a bottle of 100 tablets. The location of the manufacturer and distributor is given as Hauppauge, NY 11788 and Warren, NJ 07050 respectively.*
Cyclobenzaprine 5 mg
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.